Last quarter (Q2 2022), ABIONYX Pharma SA's total revenue was €―, a decrease of ― from the same quarter last year. In Q2, ABIONYX Pharma SA's net income was €―. See ABIONYX Pharma SA’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	€ 675.00K	€ 0.00	€ 0.00	€ 174.00K	€ 0.00
Cost of Revenue	-	€ 416.00K	€ 0.00	€ 0.00	€ 0.00	€ 0.00
Gross Profit	-	€ 259.00K	€ 0.00	€ 0.00	€ 174.00K	€ 0.00
Operating Expense	-	€ 6.21M	€ 2.97M	€ 2.52M	€ 7.23M	€ 6.64M
Operating Income	-	€ -5.95M	€ -2.97M	€ -2.52M	€ -7.05M	€ -6.64M
Net Non Operating Interest Income Expense	-	€ 148.00K	€ 1.04M	€ 4.44M	€ 775.00K	€ 1.91M
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	€ -5.82M	€ -1.89M	€ 1.89M	€ -6.30M	€ -4.98M
Tax Provision	-	€ 0.00	€ 0.00	€ 38.00K	€ 1.00K	€ 2.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	€ -5.82M	€ -1.89M	€ 1.85M	€ -6.30M	€ -4.98M
Basic EPS	-	€ -0.23	€ -0.08	€ 0.09	€ -0.34	€ -0.27
Diluted EPS	-	€ -0.23	€ -0.08	€ 0.09	€ -0.34	€ -0.27
Basic Average Shares	-	€ 24.88M	€ 22.51M	€ 20.60M	€ 18.58M	€ 18.25M
Diluted Average Shares	-	€ 25.92M	€ 23.49M	€ 21.12M	€ 19.62M	€ 19.04M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	€ 120.00K	€ 146.00K
Total Expenses	-	€ 6.63M	€ 2.97M	€ 2.52M	€ 7.23M	€ 6.64M
Net Income From Continuing And Discontinued Operation	-	€ -5.82M	€ -1.89M	€ 1.85M	€ -6.30M	€ -4.98M
Normalized Income	-	€ -5.82M	€ -1.89M	€ 1.85M	€ -6.30M	€ -4.98M
Interest Expense	-	€ 8.00K	€ 0.00	€ 350.00K	€ 0.00	€ 167.00K
EBIT	-	€ -5.81M	€ -1.89M	€ 2.24M	€ -6.30M	€ -4.81M
EBITDA	-	€ -5.70M	€ -1.89M	€ 2.25M	€ -6.26M	€ -4.22M

Currency in EUR

ABIONYX Pharma SA Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing